Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

21.41 +0.47 (+2.24%)
Streaming Delayed Price Updated: 12:38 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript ↗
CARVYKTI sales surged 50% globally as company swung to profitability. 
Via The Motley Fool
Topics Earnings
News headline image
Legend Biotech Q2 Earnings Call Highlights ↗
Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and... 
Via MarketBeat
Topics Earnings
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
It has been a banner year for biotech buyouts, and these are two of the prime targets. 
Via The Motley Fool
Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short ↗
Via Chartmill
Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q4 2025 Results, Beats on EPS ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Legend Biotech's Earnings ↗
 
Via Benzinga
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗
Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for... 
Via MarketBeat
News headline image
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With YMM Down 29%, First Beijing Bought 13 Million More Shares ↗
Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Legend Biotech (LEGN) Q1 2026 Earnings Transcript ↗
Legend Biotech (LEGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech Q1 Earnings Call Highlights ↗
Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of... 
Via MarketBeat
Topics Earnings
News headline image
Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million? ↗
Yum China operates thousands of quick-service and casual dining restaurants across China under well-known international brands. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Matthews Just Slashed Its Futu Position -- Here’s Why That Matters ↗
Futu Holdings delivers digital brokerage and wealth management services to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
News headline image
Why Legend Biotech Stock Crushed the Market on Monday ↗
Two analysts weighed in positively about the company's future. 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q4 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q2 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗
Legend Biotech (LEGN) Q4 2024 Earnings Transcript 
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Legend Biotech (LEGN) Q1 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗
Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗
Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will... 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline. 
Via The Motley Fool
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia ↗
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter ↗
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter 
Via The Motley Fool
News headline image
AMD To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.